Date: 2018-01-04
Type of information: Development agreement
Compound: up to four messenger RNA (mRNA) therapeutics for enzyme replacement and antibody generation
Company: Arcturus Therapeutics (USA - CA) Curevac (Germany)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: development
Action mechanism: mRNA.
Disease: ornithine transcarbamylase deficiency
Details:
- • On January 4, 2018, CureVac and Arcturus Therapeutics announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics. Under the agreement, the companies will collaborate to develop up to four molecular therapy products for rare diseases using Curevac’s optimized natural mRNA sequence (RNAoptimizer®) and Arcturus’s lipid-mediated nucleic acid delivery system (LUNAR™). The agreement focuses on developing mRNA therapeutics for enzyme replacement and antibody generation. Development costs will be shared between the companies, with plans to co-commercialize products in the future under a profit sharing arrangement. The first mRNA therapy to be jointly developed and potentially commercialized by the companies will target ornithine transcarbamylase (OTC) deficiency, a genetic disease characterized by the accumulation of ammonia in the blood. The collaboration also grants CureVac access to the full suite of Arcturus’s lipid-mediated delivery intellectual property to enable the development of additional mRNA product candidates.
Financial terms:
Latest news:
Is general: Yes